Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biohaven Posts Positive Migraine Results, But Investors Are Wary

Executive Summary

Biohaven's stock price fell significantly after it reported positive Phase III results for rimegepant in the acute treatment of migraine, but concerns about differences between the company's Phase II and III data eased as potential benefits over Allergan's competing oral CGRP inhibitor emerged.

Advertisement

Related Content

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven And Lilly
J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA's Gottlieb
Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches
Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis
Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues
Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab
10 First Approvals To Look Out For In 2018
Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race
Allergan migraine portfolio grows with Merck CGRP antagonists
Telcagepant failure is a headache for Merck (and perhaps Pfizer) but a break for others

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100638

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel